Fennec Pharmaceuticals Inc. carries no debt; cash flow comfortably covers obligations.

Fennec Pharmaceuticals Inc.'s free cash flow has decreased -146.23% from $26.98M last year to $-12.47M, signaling decreasing performance

Fennec Pharmaceuticals Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Fennec Pharmaceuticals Inc.'s debt has increased relative to shareholder equity from -3.29 last year to 0.00 today, signaling weakened financials

Fennec Pharmaceuticals Inc. has negative EBITDA, making leverage ratio unreliable

Fennec Pharmaceuticals Inc. carries no debt; interest obligations are fully covered.

Fennec Pharmaceuticals Inc.'s profit margin has decreased (1.69K%) in the last year from -0.92% to -16.42%, signaling decreasing performance

Fennec Pharmaceuticals Inc.'s short-term assets of $66.56M exceed its short-term liabilities of $10.50M

Fennec Pharmaceuticals Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Fennec Pharmaceuticals Inc.'s return on equity of -54.75%, is lower than 15.00%, indicating bad performance

Fennec Pharmaceuticals Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Fennec Pharmaceuticals Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Fennec Pharmaceuticals Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Fennec Pharmaceuticals Inc. has negative free cash flow, indicating cash burn

Fennec Pharmaceuticals Inc.'s yearly earnings has decreased 2.13K% since last year from $-436.00K to $-9.74M, signaling decreasing performance

Fennec Pharmaceuticals Inc.'s yearly revenue has decreased -4.45% since last year from $47.54M to $45.42M, signaling decreasing performance

ROIC -9.05% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Fennec Pharmaceuticals Inc.'s 3-year revenue CAGR of 207.52% is positive, indicating growing revenue over the past 3 years

Fennec Pharmaceuticals Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

Fennec Pharmaceuticals Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Fennec Pharmaceuticals Inc. has insufficient data to evaluate this check.

Fennec Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Fennec Pharmaceuticals Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Fennec Pharmaceuticals Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Fennec Pharmaceuticals Inc. is overvalued relative to its fair value price of -11.44 based on Earnings Fair Value model

Fennec Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Fennec Pharmaceuticals Inc. has a price-to-book ratio of 10.17x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Fennec Pharmaceuticals Inc. has a price-to-sales ratio of 7.51x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue